Regulation

Partner Therapeutics secures FDA approval for Bizengri

Partner Therapeutics has received the US Food and Drug Administration (FDA) approval for Bizengri (zenocutuzumab-zbco) to treat adults with advanced, unresectable or metastatic cholangiocarcinoma harbouring a neuregulin 1 (NRG1) gene fusion and who have progressed on or after prior systemic therapy.

BMS’ Sotyktu secures EC approval for psoriatic arthritis

Bristol Myers Squibb (BMS) has secured approval from the European Commission (EC) for Sotyktu (deucravacitinib) to treat active psoriatic arthritis (PsA).

Lannett, Lanexa Biologics and Sunshine Lake secure FDA approval for Langlara

Sunshine Lake Pharma, Lannett and its wholly owned subsidiary Lanexa Biologics have received approval from the US Food and Drug Administration (FDA) for Langlara (insulin glargine-aldy), an interchangeable biosimilar of Lantus (insulin glargine).

Arrowhead’s Redemplo secures Australian TGA approval for FCS therapy

Arrowhead Pharmaceuticals has received approval from the Australian Therapeutic Goods Administration (TGA) for Redemplo (plozasiran) to treat familial chylomicronemia syndrome (FCS).

Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitation

Axsome Therapeutics has received the US Food and Drug Administration (FDA) approval for Auvelity (dextromethorphan HBr and bupropion HCl) to treat agitation associated with dementia due to Alzheimer’s.

FDA approves AstraZeneca’s Saphnelo for SLE

AstraZeneca has received approval from the US Food and Drug Administration (FDA) for the subcutaneous self-administration of Saphnelo (anifrolumab-fnia) using the Saphnelo Pen autoinjector for systemic lupus erythematosus (SLE).

Novartis secures pair of regulatory wins for skin disease and malaria treatments

Novartis has netted a pair of regulatory wins, winning European approval for an oral therapy in chronic spontaneous urticaria (CSU) and, separately, receiving World Health Organization (WHO) prequalification for its antimalarial medication.

Travere Therapeutics gains FDA approval for sparsentan in FSGS

Travere Therapeutics has received the US Food and Drug Administration (FDA) full approval for Filspari (sparsentan) to reduce proteinuria in adult and paediatric patients aged eight years and above with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome.

MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority

Merck & Co (MSD) and Daiichi Sankyo have received priority review from the US Food and Drug Administration (FDA) for ifinatamab deruxtecan’s biologics licence application (BLA) to treat extensive-stage small cell lung cancer (ES-SCLC).